Results 71 to 80 of about 34,399 (185)
Polypoidal Choroidal Vasculopathy Secondary to Sclerochoroidal Calcification
, 2017 Purpose: To present a case of polypoidal choroidal vasculopathy secondary to sclerochoroidal calcification. Method: A single patient case report with multimodal imaging including color fundus, red free and autofluorescence photography, fluorescein and ...
I-Van Ho +4 more
core +1 more source
Recent Advancements in the Treatment of Age‐Related Macular Degeneration
Med Research, Volume 1, Issue 2, Page 151-169, September 2025.ABSTRACT Age‐related macular degeneration (AMD) is a prevalent cause of visual impairment and blindness among the elderly. AMD can be categorized into two subtypes: “wet” and “dry.” Current treatments for wet AMD mainly involve anti‐vascular endothelial growth factor (VEGF) drugs, and there are three U.S.
Shan Liu +10 more
wiley +1 more source
Polypoidal choroidal vasculopathy secondary to a stable choroidal nevus
, 2016 Choroidal nevus is the most common ocular fundus tumor in adults. Previous studies have widely discussed the features of choroidal neovascularization secondary to nevus and its treatment options.
Lai, Xin Jie +4 more
core +1 more source
Performance of ChatGPT on optometry and vision science exam questions
Ophthalmic and Physiological Optics, Volume 45, Issue 6, Page 1376-1388, September 2025.Abstract The rapid proliferation of Large Language Models (LLM) tools, such as ChatGPT developed by OpenAI, presents both a challenge and an opportunity for educators. While LLMs can generate convincing written responses across a wide range of academic fields, their capabilities vary noticeably across different models, fields and even sub‐fields.
Nayuta Yoshioka +5 more
wiley +1 more source
, 2021 Purpose: This work compares the relative cost utility of ranibizumab and aflibercept with and without verteporfin photodynamic therapy (vPDT) for the treatment of polypoidal choroidal vasculopathy.
Feng, Paula W +8 more
core +1 more source
Safety of an Intravitreal Bevacizumab Biosimilar (MVASI)
Clinical &Experimental Ophthalmology, Volume 53, Issue 5, Page 523-528, July 2025.ABSTRACT Background Intravitreal bevacizumab has been used off‐label to treat multiple ocular conditions for almost two decades. Reference bevacizumab, Avastin, was discontinued in Australia in 2021. A bevacizumab biosimilar, MVASI, was approved by the Therapeutic Goods Administration for the treatment of metastatic cancer in 2020.
Hanru Wang +8 more
wiley +1 more source
Polypoidal choroidal vasculopathy: a comprehensive clinical update
Therapeutic Advances in Ophthalmology, 2019 Polypoidal choroidal vasculopathy as a disease is yet to be comprehended completely. The clinical features consisting of huge serosanguineous retinal pigment epithelial and neurosensory layer detachments, although unique may closely mimick neovascular ...
Atul Kumar +8 more
doaj +1 more source
Advanced Intelligent Systems, Volume 7, Issue 4, April 2025.The proposed artificial intelligence model, cross‐subject meta‐transfer learning, enables the automatic detection of vitreoretinal lymphoma (VRL) on optical coherence tomography images among 16 retinal diseases and conditions. This study provides an innovative solution to assist in the VRL diagnosis in real‐world clinical implementation, showing ...
Aidi Lin +23 more
wiley +1 more source
, 2018 Changes in choroidal area in polypoidal choroidal vasculopathy (PCV) with intravitreal aflibercept injections.
Jinhee Lee (226004) +8 more
core +1 more source
, 2019 PURPOSE: To investigate the prevalence of a newly defined drusen type, pachydrusen, soft drusen, and subretinal drusenoid deposits in eyes with polypoidal choroidal vasculopathy and fellow eyes and the relationship between each drusen type and the ...
이준원, 변석호
core +1 more source